Medline Q3 2026 adjusted EBITDA rises 12% to $960 million

Bitget2026/11/04 13:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Medline’s Q3 2026 adjusted EBITDA rose 12% year over year to $960 million.
Net IEEPA tariff refund benefits contributed $81 million to adjusted EBITDA in the quarter.
A share repurchase program of up to $1 billion was authorized in October 2026.
FY26 organic sales growth guidance increased to 10%–10.5%, from 9%–10%.
Adjusted EBITDA guidance remained $3.3 billion–$3.4 billion, excluding tariff refund benefits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medline Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Medline Q3 2026 adjusted EBITDA rises 12% to $960 million

You may also like

Crypto prices